TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8406966

Group type: EXPERIMENTAL
Intervention: alpha‐phase gutta‐percha on a plastic Thermafil carrier
Number of subjects: 51

Group type: COMPARATOR
Intervention: standard beta‐phase gutta‐percha with lateral condensation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both techniques (Thermafil and lateral condensation)
Number of subjects: 51
Study: 3022664

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Desipramine-yohimbine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Desipramine-lithium carbonate or lithium carbonate-tranylcypromine sulfate combination treatment
Number of subjects: 21
Study: 31599351

Group type: EXPERIMENTAL
Intervention: CBT + treatment as usual (TAU)
Number of subjects: 25

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 25
Study: 30224269

Group type: EXPERIMENTAL
Intervention: Calmer Life (CL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Community Care with Resource Counseling (ECC-RC)
Number of subjects: 0
Study: 26647769

Group type: EXPERIMENTAL
Intervention: Extended sleep (21.00-07.00 h time in bed, EXT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Habitual sleep (22.30-07.00 h time in bed, HAB)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (24 h and 34 h of continuous awakening)
Number of subjects: 14
Study: 25263836

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle modification programme (specific health guidance)
Number of subjects: 3480

Group type: COMPARATOR
Intervention: 1% to <3% weight reduction group
Number of subjects: 3480

Group type: EXPERIMENTAL
Intervention: 3% to <5% weight reduction group
Number of subjects: 3480

Group type: EXPERIMENTAL
Intervention: ≥5% weight reduction group
Number of subjects: 3480
Study: 22864399

Group type: EXPERIMENTAL
Intervention: Persistence on the stress-challenge task before initiating buprenorphine treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Antidepressant and placebo groups
Number of subjects: 48
Study: 19350648

Group type: EXPERIMENTAL
Intervention: Body image intervention (3 sessions of 50 minutes each)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual classes (Control)
Number of subjects: 194
Study: 18056186

Group type: EXPERIMENTAL
Intervention: Imatinib (first-line)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Imatinib (second-line)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sustained detectable BCR-ABL (control group)
Number of subjects: 53
Study: 15854186

Group type: EXPERIMENTAL
Intervention: Cophenylcaine nasal spray
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 98
Study: 12162475

Group type: EXPERIMENTAL
Intervention: Film-coated tablets (FCT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aqueous solution (AS)
Number of subjects: 16
Study: 12884889

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Clinical management (Control)
Number of subjects: 158
Study: 10336001

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biotin-labeled platelets
Number of subjects: 0
Study: 1984901

Group type: EXPERIMENTAL
Intervention: Transesophageal Doppler color flow imaging
Number of subjects: 42

Group type: COMPARATOR
Intervention: Transthoracic Doppler color flow imaging
Number of subjects: 42
Study: 6411230

Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion starting at 2 U/hour for adolescents, 4 U/hour for adults, and 6 U/hour for patients with acromegaly
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion
Number of subjects: 25
Study: 31957345

Group type: EXPERIMENTAL
Intervention: Saudi Diabetes Risk Score (SADRISC)
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: SADRISC
Number of subjects: 1403
Study: 30582194

Group type: EXPERIMENTAL
Intervention: Media Smart-Targeted (MS-T) program (9-module program released weekly)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Positive body image tips (control group)
Number of subjects: 316
Study: 28477269

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires regarding awareness and knowledge of cervical cancer
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires regarding attitudes towards cervical cancer screening and prevention
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Overall awareness and knowledge assessment
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Overall attitude assessment
Number of subjects: 450
Study: 23623564

Group type: EXPERIMENTAL
Intervention: HF symptom training intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study: 21737382

Group type: EXPERIMENTAL
Intervention: Additional mental practice during the interval between the two training sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard training without additional mental practice)
Number of subjects: 40
Study: 19842422

Group type: EXPERIMENTAL
Intervention: Triclosan/PVM/MA copolymer mouthrinse
Number of subjects: 0
Study: 17426065

Group type: EXPERIMENTAL
Intervention: Anti-TNF treatments (etanercept, infliximab, adalimumab) in RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DREAM patients eligible for RCTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: DREAM patients
Number of subjects: 0
Study: 15115499

Group type: EXPERIMENTAL
Intervention: PUVA (twice weekly for 3 months)
Number of subjects: 16

Group type: COMPARATOR
Intervention: ECP (once monthly for 6 months at relapse)
Number of subjects: 16
Study: 11962245

Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 24-hour recall
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 3-day food records
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Traditional correlation testing
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Nontraditional method
Number of subjects: 104
Study: 9149168

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus surgery plus radiotherapy (arm A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Chemotherapy plus radiotherapy alone (arm B)
Number of subjects: 92
Study: 7955803

Group type: EXPERIMENTAL
Intervention: Ethoxyidazoxan 6 micrograms/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ethoxyidazoxan 8 micrograms/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3602266

Group type: EXPERIMENTAL
Intervention: Caffeine 125 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (3 mg)
Number of subjects: 36
Study: 29380026

Group type: EXPERIMENTAL
Intervention: Stigma stress at baseline
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Anti-stigma interventions
Number of subjects: 186
Study: 27914503

Group type: EXPERIMENTAL
Intervention: TAVR with Edwards SAPIEN 3 Transcatheter Heart Valve plus optimal heart failure therapy (OHFT)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Optimal heart failure therapy (OHFT) alone
Number of subjects: 600
Study: 25148183

Group type: EXPERIMENTAL
Intervention: Shear-wave elastography at biopsy site
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shear-wave elastography at ipsilateral lobe
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shear-wave elastography at contralateral lobe
Number of subjects: 50

Group type: COMPARATOR
Intervention: Steatosis and serum markers
Number of subjects: 50
Study: 23233021

Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20826632

Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling (LC)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling + Flaxseed (LCF) 30 g/d
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling + Walnuts (LCW) 30 g/d
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control Group (LC)
Number of subjects: 283
Study: 18458842

Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16398803

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin (GTN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 40
Study: 14514130

Group type: EXPERIMENTAL
Intervention: 100 mg LJP 394 weekly for 16 weeks followed by three 12-week treatment cycles of 50 mg LJP 394 weekly
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: LJP 394
Number of subjects: 179
Study: 10571358

Group type: EXPERIMENTAL
Intervention: Loop haptic IOL
Number of subjects: 48

Group type: COMPARATOR
Intervention: Plate haptic IOL
Number of subjects: 48
Study: 8991843

Group type: EXPERIMENTAL
Intervention: 2% ethanol added to distension medium during ablative hysteroscopy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intraoperative ethanol monitoring
Number of subjects: 120

Group type: COMPARATOR
Intervention: Procedures with minimal endometrial injury (e.g., syneciolysis, hysteroscopic proximal tubal catheterisation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ablative procedures (e.g., resection of myoma, endometrium ablation, septum resection)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Breath alcohol, amount of absorbed fluid, haematocrit and haemoglobin values, central venous pressure, heart frequency
Number of subjects: 120
Study: 10147023

Group type: EXPERIMENTAL
Intervention: Early thrombolysis (less than 3 hours)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Late thrombolysis (greater than 3 hours)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Thrombolysis for posterior infarcts
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Thrombolysis for anterior infarcts
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Quality of life post-AMI
Number of subjects: 167
Study: 6696208

Group type: EXPERIMENTAL
Intervention: Terbutaline 65 micrograms
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Terbutaline 250 micrograms
Number of subjects: 13
Study: 30951926

Group type: EXPERIMENTAL
Intervention: Clinical trial participation for newly diagnosed glioblastoma (nGBM)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Clinical trial participation for recurrent glioblastoma (rGBM)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Trial eligible but received standard care
Number of subjects: 755

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Demographic characteristics of nGBM trial participants
Number of subjects: 755

Group type: COMPARATOR
Intervention: Comparison of eligible non-participants
Number of subjects: 755
Study: 30195616

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral regimen
Number of subjects: 601

Group type: COMPARATOR
Intervention: No antiviral treatment
Number of subjects: 601
Study: 26762481

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 392

Group type: COMPARATOR
Intervention: Heparin with or without tirofiban
Number of subjects: 392
Study: 24170449

Group type: EXPERIMENTAL
Intervention: Senior medical students
Number of subjects: 99

Group type: COMPARATOR
Intervention: Junior doctors
Number of subjects: 99
Study: 22340303

Group type: EXPERIMENTAL
Intervention: Digital photographs for diagnosing HOA
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Digital photographs for predicting pain on most days for at least a month in females
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Digital photographs for diagnosing intermittent pain in DIP and PIP joints
Number of subjects: 381

Group type: COMPARATOR
Intervention: Radiography for predicting pain in CMC1 joints
Number of subjects: 381

Group type: COMPARATOR
Intervention: Clinical examination for predicting pain in CMC1 joints
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Digital photographs for diagnosing HOA using a shortened method
Number of subjects: 381
Study: 20339369

Group type: EXPERIMENTAL
Intervention: risperidone plus mifepristone
Number of subjects: 76

Group type: COMPARATOR
Intervention: risperidone plus placebo
Number of subjects: 76
Study: 17385265

Group type: EXPERIMENTAL
Intervention: L-NAME (1 mg/kg) administered intravenously over 60 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo administered intravenously over 60 minutes
Number of subjects: 14
Study: 15718412

Group type: EXPERIMENTAL
Intervention: Resistance exercise (9 resistance exercises at 75% of 1 repetition maximum)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham control (seated rest in the exercise room)
Number of subjects: 16
Study: 11978255

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once a day for 10 days
Number of subjects: 196

Group type: COMPARATOR
Intervention: amoxicillin 500 mg three times per day for 10 days
Number of subjects: 196
Study: 9436066

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Postpartum
Number of subjects: 52
Study: 7897786

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention with increased intensity and frequency of visits (visits with primary care physician and psychiatrist) and continued surveillance of adherence to medication regimens.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 217
Study: 2087821

Group type: EXPERIMENTAL
Intervention: Anthraquinone containing laxative
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no anthraquinone laxative)
Number of subjects: 22
Study: 358472

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31580714

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Western Medicine (WM)
Number of subjects: 469
Study: 28641875

Group type: EXPERIMENTAL
Intervention: Onlay mesh reinforcement
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Sublay mesh reinforcement
Number of subjects: 480

Group type: COMPARATOR
Intervention: Primary suture only
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 480
Study: 25644096

Group type: EXPERIMENTAL
Intervention: Budesonide foam 2 mg/25 mL twice daily for 2 weeks, then once daily for 4 weeks
Number of subjects: 546
Study: 23597323

Group type: EXPERIMENTAL
Intervention: Guided self-instruction
Number of subjects: 261

Group type: COMPARATOR
Intervention: Wait list (Control)
Number of subjects: 261
Study: 21714792

Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) pacing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Left ventricle (LV) pacing
Number of subjects: 21

Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 21
Study: 19147636

Group type: EXPERIMENTAL
Intervention: Psychologically informed sessions by trained health visitors for one hour a week for eight weeks.
Number of subjects: 4084

Group type: COMPARATOR
Intervention: Usual care provided by health visitors in the control group.
Number of subjects: 4084
Study: 16987710

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No antiretroviral therapy
Number of subjects: 68
Study: 12631652

Group type: EXPERIMENTAL
Intervention: Baclofen (acute administration for 24 hours)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Baclofen (chronic administration for four weeks, 10 mg four times daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (acute administration for 24 hours)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (chronic administration for four weeks)
Number of subjects: 43
Study: 10691866

Group type: EXPERIMENTAL
Intervention: 2‐CdA + prednisone
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 2‐CdA alone
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 2‐CdA
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Infections and fever of unknown origin
Number of subjects: 378
Study: 9360661

Group type: EXPERIMENTAL
Intervention: 100 mg intravenous iron once weekly
Number of subjects: 17

Group type: COMPARATOR
Intervention: 50 mg intravenous iron twice weekly
Number of subjects: 17
Study: 7505159

Group type: EXPERIMENTAL
Intervention: Detailed written information about maternal‐serum alpha‐fetoprotein testing
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Anxiety management training
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Combination of detailed written information and anxiety management training
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Completion of study questionnaires
Number of subjects: 85

Group type: COMPARATOR
Intervention: Receipt of abnormal alpha‐fetoprotein result
Number of subjects: 85
Study: 3544665

Group type: EXPERIMENTAL
Intervention: Silastic cup of Kobayashi
Number of subjects: 100

Group type: COMPARATOR
Intervention: Malmström extractor
Number of subjects: 100
Study: 30339891

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Midazolam (M group)
Number of subjects: 102
Study: 30016743

Group type: EXPERIMENTAL
Intervention: SafeCare Dad2K
Number of subjects: 99

Group type: COMPARATOR
Intervention: Comparison group (receiving parenting information in the mail)
Number of subjects: 99
Study: 26847970

Group type: EXPERIMENTAL
Intervention: Auto-servo ventilation (ASV)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Optimal medical treatment alone (control)
Number of subjects: 63
Study: 23446198

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (specific medication not mentioned)
Number of subjects: 439
Study: 22891225

Group type: EXPERIMENTAL
Intervention: Maternal-focused anticipatory guidance (MOMS)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Infant-focused anticipatory guidance (Ounce of Prevention)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Routine advice (Bright Futures)
Number of subjects: 292
Study: 20606083

Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg once daily)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Lapatinib (1,500 mg once daily)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Lapatinib plus Pazopanib (1,000 mg plus 400 mg once daily or 1,500 mg plus 800 mg once daily)
Number of subjects: 230
Study: 17209214

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation
Number of subjects: 0
Study: 15867239

Group type: EXPERIMENTAL
Intervention: 17AAG (10 to 395 mg/m2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 17AAG (10 to 295 mg/m2)
Number of subjects: 45
Study: 12362100

Group type: EXPERIMENTAL
Intervention: EUBT with 100 mg of (13)C-urea
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: EUBT with 50 mg of (13)C-urea
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: EUBT with 25 mg of (13)C-urea
Number of subjects: 325
Study: 10466665

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: E. coli (Nissle 1917)
Number of subjects: 116
Study: 7838898

Group type: EXPERIMENTAL
Intervention: Alprazolam therapy (2-2.5 mg for 30 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (10 psychophysically healthy controls)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHRH stimulation (1 microgram/kg b.w.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine stimulation (150 micrograms)
Number of subjects: 10
Study: 1707298

Group type: EXPERIMENTAL
Intervention: GM-CSF (75, 150, 300, or 600 micrograms protein/day, administered SC twice a day for 5 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 477008

Group type: EXPERIMENTAL
Intervention: Selective shunt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total shunt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31939363

Group type: EXPERIMENTAL
Intervention: SRP + Photodynamic therapy (using Indocyanine green)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 30
Study: 28075507

Group type: EXPERIMENTAL
Intervention: Induction of labour at 39 weeks
Number of subjects: 0
Study: 25998923

Group type: EXPERIMENTAL
Intervention: Cancer survivors
Number of subjects: 245283
Study: 23715630

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg once daily
Number of subjects: 298

Group type: COMPARATOR
Intervention: Anastrozole 1 mg once daily
Number of subjects: 298
Study: 20657034

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 750

Group type: COMPARATOR
Intervention: Interferon-α (IFN-α)
Number of subjects: 750
Study: 19583878

Group type: EXPERIMENTAL
Intervention: Dark chocolate (50 g daily dose with 70% cocoa containing 750 mg polyphenols)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tomato extract (one capsule containing 15 mg lycopene per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (one capsule daily)
Number of subjects: 36
Study: 17299503

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15494087

Group type: EXPERIMENTAL
Intervention: Videoconferencing PTSD coping skills group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Face-to-face PTSD coping skills group
Number of subjects: 20
Study: 11284758

Group type: EXPERIMENTAL
Intervention: Topical Ketorolac trometamol 0.5% ophthalmic solution
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo Liquifilm tears
Number of subjects: 88
Study: 9210073

Group type: EXPERIMENTAL
Intervention: Swaddled weighing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Unsaddled weighing
Number of subjects: 14
Study: 8190431

Group type: EXPERIMENTAL
Intervention: Strict control (n=68): fasting blood glucose < 4.44 mmol/L and postprandial blood glucose < 6.66 mmol/L
Number of subjects: 137

Group type: COMPARATOR
Intervention: Customary control (n=69): fasting blood glucose < 5.55 mmol/L and postprandial blood glucose < 7.77 mmol/L
Number of subjects: 137
Study: 3110944

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (SATM)
Number of subjects: 120
Study: 30476251

Group type: EXPERIMENTAL
Intervention: Atorvastatin (starting dose 80 mg PO daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80